TRANSCAN-3 JTC2021 International Networking Event



Bu proje Avrupa Birliği ve Türkiye Cumhuriyeti tarafından finanse edilmektedir



Miguel Moreno AptusBiotech

miguel.moreno@aptusbiotech.com











- Aptus Biotech is a biotech start-up R&D performing SME whose main goal is the development of new biotechnological applications based on aptamer technology.
- **Aptamers** are artificial nucleic acid ligands (short single-stranded DNA or RNA) that present high association constants with target proteins, relatively easy and reproducible production and labelling, cost-effectiveness and stability during long-term storage.
- Aptus carried out the initial stages of the development and characterization of an **aptamer against TLR4.** AptaTargets purchased the molecule and initiated the ApTOLL program towards the treatment of acute ischemic stroke. Currently, the molecule is in **clinical trials phase IIa**.
- Nowadays, Aptus is seeking novel applications of our aptamer technology. Particularly, the company is focused on our APTABREAST project that aims to overcome the preclinical phase (non-regulatory and regulatory) by the Mnk1 aptamer (apMNKQ2) development for breast cancer novel therapy.










TÜRİTAL

Our Technology: Aptamers

Aptamers: a promising technology in pharmacology

- **1.** Nucleic acids capable of binding to specific target molecules due to the acquisition of a stable 3D structure.
- **2. Selected** *in vitro* depending on the specificity of binding with a particular target from millions of random sequences.
- 3. Show relevant advantages and are a **clear alternative to antibodies**.











Specific recognition and stable





Please indicate relevant JTC2021 aim and sub aims

Aim 1: Identification and validation of tumour microenvironment (TME) subclasses and their contribution to the resistance mechanisms

Aim 2: Targeting TME to improve efficacy of immunotherapy in human patients.

We offer our APTAMER CUSTOM SERVICE as a tool to generate novel tools targeting TME to improve immunotherapy efficacy













Miguel Moreno AptusBiotech CSO Spain <u>miguel.moreno@aptusbiotech.com</u> www.aptusbiotech.com







